Justpoint is a technology company.
Justpoint has raised $53.0M across 3 funding rounds.
Key people at Justpoint.
Justpoint has raised $53.0M in total across 3 funding rounds.
Key people at Justpoint.
Justpoint has raised $53.0M in total across 3 funding rounds.
Justpoint's investors include Lightbank, Right Side Capital Management, 01 Advisors, 9Yards Capital, AAF Management Ltd., Afore Capital, AirAngels, Akshay Kothari, Ali Moiz, Andreessen Horowitz, Antiportfolio Ventures, Backed VC.
Justpoint is an AI-powered legal tech startup that analyzes medical, legal, and scientific data to detect harmful products, drugs, and toxins—such as those in ultra-processed foods, GLP-1 medications, and consumer goods like talc-based baby powder—enabling early identification of personal injury claims and mass tort litigations.[1][2][4] It serves consumers harmed by toxic exposures and law firms seeking viable cases, solving the problem of undetected product dangers that regulatory bodies like the FDA often miss by years, while helping victims secure higher settlements (averaging $355,000 per case) and driving systemic change through litigation.[2][4] With 21 employees as of 2023, Justpoint has raised over $158M total—including a $95M round—and processes over 1,000 claims daily, showing strong growth (6.29% weekly, 97th percentile).[1][2]
Justpoint emerged from founder and Chairman Victor Bornstein, Ph.D., whose background blends AI, healthtech, biotech, and legal expertise, driven by a personal mission to protect consumers from toxic exposures.[1][2] The idea took shape in the 2010s amid growing awareness of product-related harms, evolving from an initial focus on personal injury claim analysis for plaintiffs and law firms to a broader platform tackling the "toxic exposure epidemic" using AI on billions of data points.[1][4] Pivotal early traction included a $6.9M seed round in March 2022 (pre-money valuation $17M, led by Charge Ventures and Divergent Capital), followed by a massive $95M raise to scale detection of dangerous drugs and chemicals, with early wins like spotting risks in Oxbryta 21 months before its withdrawal.[1][2]
Justpoint rides the AI-legal tech wave intersecting healthtech and consumer safety, capitalizing on exploding mass tort opportunities from toxic products amid regulatory lags—e.g., decades-long talc cancer links or emerging GLP-1 drug risks like stomach paralysis.[2][4] Timing is ideal post-2020s shifts, like J&J's talc withdrawal, as AI unlocks underserved markets in personal injury and malpractice, where conventional research trails real harm.[1][4] Favorable forces include vast datasets from medical/scientific sources, rising plaintiff volumes, and investor appetite (backers like SignalFire, Lightbank), positioning Justpoint to influence ecosystems by spurring regulations, safer products, and a new litigation infrastructure that scales consumer protection.[2]
Justpoint is poised to dominate AI-driven toxic exposure detection, with its data moat and $95M war chest fueling expansion into more categories like food additives and contaminants, potentially processing millions of claims annually.[2][4] Trends like advanced LLMs, mass tort proliferation, and consumer activism will accelerate its growth, evolving it from claim matcher to industry standard-setter—perhaps pressuring FDA reforms or birthing AI-native law practices. As AI uncovers "hidden toxins" faster, Justpoint could redefine trust in everyday products, turning personal injury tech into a trillion-dollar safeguard.
Justpoint has raised $53.0M across 3 funding rounds. Most recently, it raised $45.0M Series A in January 2025.
